Document Detail


Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?
MedLine Citation:
PMID:  20194711     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Amylin, cosecreted with insulin, has like glucagon-like peptide-1 (GLP-1) been reported to inhibit glucagon secretion, delay gastric emptying, and reduce appetite and food intake. We investigated whether the effects of GLP-1 on gastric emptying, appetite, and food intake are mediated directly or indirectly via release of amylin.
DESIGN: Eleven C-peptide and amylin-negative patients with type 1 diabetes mellitus (T1DM) and 12 matched healthy controls participated in a placebo-controlled, randomized, single-blinded, crossover study. With glucose clamped between 6 and 9 mm, near-physiological infusions of GLP-1, human amylin, pramlintide, or saline were given for 270 min during and after a fixed meal. Gastric emptying was measured using paracetamol, appetite using visual analog scales, and food intake during a subsequent ad libitum meal (at 240 min).
RESULTS: In T1DM, gastric emptying, food intake, and appetite were reduced equally during low GLP-1 and amylin infusion compared with the saline infusion (P < 0.05). The controls showed stronger suppression of gastric emptying (P < 0.0001) and food intake (P < 0.01) with GLP-1 compared to amylin. Postprandial glucagon responses were reduced in controls and T1DM during GLP-1 and amylin infusions (P < 0.05). Amylin and pramlintide infusion had similar effects.
CONCLUSIONS: GLP-1 exerts its effect on gastric emptying, appetite, food intake, and glucagon secretion directly, although secretion of amylin may contribute to some of these effects in healthy control subjects.
Authors:
Meena Asmar; Michael Bache; Filip K Knop; Sten Madsbad; Jens J Holst
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-03-01
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  95     ISSN:  1945-7197     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-05-06     Completed Date:  2010-05-28     Revised Date:  2013-11-25    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2367-75     Citation Subset:  AIM; IM    
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00876231
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Amyloid / blood,  pharmacology,  secretion*
Appetite / drug effects*,  physiology
Body Mass Index
C-Peptide / blood
Cross-Over Studies
Diabetes Mellitus, Type 1 / physiopathology*
Gastric Emptying / drug effects*,  physiology
Glucagon / antagonists & inhibitors,  secretion
Glucagon-Like Peptide 1 / blood,  pharmacology*
Hemoglobin A, Glycosylated / metabolism
Humans
Hypoglycemic Agents / pharmacology
Insulin / secretion
Islet Amyloid Polypeptide
Reference Values
Single-Blind Method
Chemical
Reg. No./Substance:
0/Amyloid; 0/C-Peptide; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Insulin; 0/Islet Amyloid Polypeptide; 89750-14-1/Glucagon-Like Peptide 1; 9007-92-5/Glucagon; D3FM8FA78T/pramlintide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adipokines and Cardiometabolic Profile in Primary Hyperaldosteronism.
Next Document:  Individualizing Therapies in Type 2 Diabetes Mellitus Based on Patient Characteristics: What We Know...